TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2066762
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/mq, doxorubicin 45 mg/mq, and cyclophosphamide 600 mg/mq (PAC)
Study: 31922425
Drug: Second-line therapies
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line therapies
Study: 26840067
Drug: Food Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Food Insulin Demand (FID) counting
Study: 26840067
Drug: Carbohydrate Counting
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate Counting (CC)
Study: 15798683
Drug: CRN (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRN (no root canal treatment, restored with a crown)
Study: 9498640
Drug: [N(ε)‐palmitoyl Lys
Approvals — FDA: no, EMA: no, PMDA: no
Description: [N(ε)‐palmitoyl Lys (B29)] human insulin
Study: 31828753
Drug: Restrictive intravenous
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive intravenous (IV) fluid therapy
Study: 31828753
Drug: Standard-care intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-care intravenous (IV) fluid therapy
Study: 29254987
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitors (DPP‐4is)
Study: 27373605
Drug: Concentrate formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate formulation
Study: 25287144
Drug: Serelaxin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin (30 µg/kg per day)
Study: 21659904
Drug: Nonalcoholic beer
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonalcoholic beer (NAB) 1-1.5 L · d(‐1) for 3 weeks before and 2 weeks after the marathon
Study: 9210061
Drug: All-trans-retinoic acid
Normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans-retinoic acid (tretinoin) at 120 or 150 mg/m2/day for 3 weeks followed by 1 week of rest, given as a single agent.
Study: 27221567
Drug: PM2.5 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM2.5 (150 μg/m(3))
Study: 27221567
Drug: Ozone (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone (240 μg/m(3))
Study: 24366937
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg orally daily for 2 years
Study: 17090282
Drug: Tegaserod 2
Normalized name: tegaserod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 2 mg b.i.d.
Study: 12839848
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy with FLAC/granulocyte-colony-stimulating factor
Study: 10663415
Drug: bupropion 300
Normalized name: buPROPion 300 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion 300 mg/day
Study: 10663415
Drug: bupropion 150
Normalized name: BUPROPION 150MG (SMK-C) 12HR SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion 150 mg/day
Study: 29383896
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment + acupuncture therapy (observation group)
Study: 27798895
Drug: Oral tegafur/gimeracil/oteracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tegafur/gimeracil/oteracil (S‐1)
Study: 20658835
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group writing about facts of diagnosis and treatment (CTL; n = 31)
Study: 16022024
Drug: Oral-B
Normalized name: Oral-B Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B
Study: 11805503
Drug: BioMask treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioMask treatment with excimer laser phototherapeutic keratectomy (PTK)
Study: 9916956
Drug: Depot leuprolide
Normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot leuprolide (3.75 mg/mo)
Study: 7583865
Drug: Perfume inhalation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perfume inhalation from magazine scent strips
Study: 2305013
Drug: Scopolamine 0.22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.22 mg/70 kg
Study: 2305013
Drug: Scopolamine 0.43
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.43 mg/70 kg
Study: 2305013
Drug: Scopolamine 0.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.65 mg/70 kg
Study: 348535
Drug: Mianserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (10 mg t.d.s. for the first week, increasing to 20 mg t.d.s. for the subsequent three weeks)
Study: 348535
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg t.d.s. for the first week, increasing to 50 mg t.d.s. for the subsequent three weeks)
Study: 28291862
Drug: Splinted prostheses
Normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Splinted prostheses with short implants (short group SP)
Study: 28291862
Drug: Nonsplinted prostheses
Normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsplinted prostheses with regular implants (regular group NSP)
Study: 28291862
Drug: Splinted prostheses
Normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Splinted prostheses with regular implants (regular group SP)
Study: 28291862
Drug: Nonsplinted prostheses
Normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsplinted prostheses with short implants (short group NSP)
Study: 20497432
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (group I)
Study: 20497432
Drug: Peribulbar triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peribulbar triamcinolone orbital injection (group II)
Study: 16324269
Drug: Capsaicin inhalation
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin inhalation cough challenge test by dosimeter method
Study: 12826636
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of oral prednisone once daily for 10 days
Study: 8651227
Drug: multiple vitamin/mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple vitamin/mineral supplement
Study: 2052468
Drug: Volmax 8
Normalized name: Volmax 8mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volmax 8 mg orally every 12 hours for 3 days
Study: 2052468
Drug: Proventil Repetabs
Normalized name: Proventil Repetabs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proventil Repetabs 8 mg orally every 12 hours for 3 days
Study: 28091350
Drug: High-flavanone (HF;
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanone (HF; 70.5 mg) drink
Study: 23713782
Drug: KOH 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: KOH 5% solution
Study: 23713782
Drug: KOH 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: KOH 2.5% solution
Study: 23801093
Drug: Commercial immuno-enhancing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial immuno-enhancing supplement 5 days preoperatively
Study: 28848225
Drug: No supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplements (Control)
Study: 14998080
Drug: Intravenous moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moxifloxacin 400 mg once-daily
Study: 14998080
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin 400 mg once-daily
Study: 29907335
Drug: Mindfulness-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based intervention (weekly sessions for 8 weeks)
Study: 22876442
Drug: Basic weight-reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic weight-reduction treatment (Control group)
Study: 10793433
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT), n = 25
Study: 10793433
Drug: No Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Therapy (NT), n = 24
Study: 8656502
Drug: Lamivudine 150
Normalized name: lamivudine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 150 mg every 12 hours plus zidovudine
Study: 8656502
Drug: Lamivudine 300
Normalized name: lamivudine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 300 mg every 12 hours plus zidovudine
Study: 17377691
Drug: 0.3% Triclosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% Triclosan varnish applied twice a year (every half year) for one year.
Study: 15704508
Drug: 12 additional
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 additional therapy sessions (over four weeks) comprising exercises aimed at improving lateral weight transference in sitting delivered by trained physiotherapy assistants
Study: 11897208
Drug: niacin/lovastatin 500/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin/lovastatin 500/10 mg
Study: 11897208
Drug: niacin/lovastatin 1,000/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin/lovastatin 1,000/20 mg
Study: 11897208
Drug: niacin/lovastatin 1,500/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin/lovastatin 1,500/30 mg
Study: 11897208
Drug: niacin/lovastatin 2,000/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin/lovastatin 2,000/40 mg
Study: 9854276
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery therapy for 6 weeks
Study: 9854276
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery therapy
Study: 8548055
Drug: High-dose progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose progesterone (0.714 mg.kg‐1.h‐1 for 60 min followed by 0.45 mg.kg‐1.h‐1 over 315 min)
Study: 8548055
Drug: High-dose progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose progesterone
Study: 28118454
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment during washout
Study: 26414234
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (CES device turned on and off)
Study: 23472927
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous cephalothin
Study: 23472927
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous cephalothin plus oral amoxicillin/clavulanate for 7 days
Study: 19183157
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 90 mg in moderate-to-severe EO
Study: 9542607
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with birch-pollen extract
Study: 3349417
Drug: Protein A
Normalized name: Protein antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein A treatment (Prosorba column containing 50 or 200 mg protein A, administered 12 times either once per week or three times per week)
Study: 3349417
Drug: Protein A
Normalized name: Protein antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein A treatment (Prosorba column)
Study: 28882371
Drug: Dexmedetomidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.1 mg kg−1) and midazolam (1.0 mg kg−1)
Study: 28882371
Drug: Alfaxalone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (15 mg kg−1) and midazolam (1.0 mg kg−1)
Study: 23873559
Drug: Added P
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Added P from KH2PO4 at levels of 0, 0.7, 1.4, or 2.1 g/kg of diet
Study: 23873559
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 5 g of highly soluble calcium (HSC)
Study: 15582348
Drug: Self-treatment program
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-treatment program with additional information on recognizing prodromal signs and doubling inhaled corticosteroids (ICS) during one week
Study: 15582348
Drug: Structured information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured information on asthma, symptoms, and medication
Study: 1387351
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil (150 micrograms)
Study: 4076202
Drug: Metoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (10 mg)
Study: 3793280
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Nisoldipine + Metoprolol)
Study: 3793280
Drug: Order of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Order of administration (Nisoldipine added to Metoprolol)
Study: 29359848
Drug: Weight-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based treatment (0.3 g glucose/kg body-weight)
Study: 29359848
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 12 g glucose
Study: 29359848
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 30 g glucose
Study: 17462639
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist trigger after cotreatment with GnRH antagonist
Study: 17462639
Drug: hCG trigger
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG trigger after dual pituitary suppression with a GnRH agonist
Study: 15982504
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C administration
Study: 11865815
Drug: TMTX/5-FU/LV (TMTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMTX/5-FU/LV (TMTX 110 mg/m2 i.v. followed by LV 200 mg/m2/5-FU 500 mg/m2 plus oral LV rescue)
Study: 11865815
Drug: 5-FU/LV (5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/LV (5-FU 600 mg/m2 in Europe and 500 mg/m2 in USA)
Study: 8938912
Drug: Haloperidol treatment
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol treatment
Study: 2861844
Drug: Terfenadine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine and Cimetidine (in combination)
Study: 30207844
Drug: Continuous diffusion
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous diffusion of oxygen (CDO) therapy
Study: 24389521
Drug: Circuit resistance
Normalized name: BREATHING CIRCUIT W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circuit resistance training (CRT) performed three times weekly for 40‐45 min each session with immediate protein supplementation (PS) of whey protein = 36‐37 g before and after exercise
Study: 24389521
Drug: Circuit resistance
Normalized name: BREATHING CIRCUIT W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circuit resistance training (CRT) performed three times weekly for 40‐45 min each session with delayed protein supplementation (PS) of matched protein dose 24 h postexercise
Study: 22153143
Drug: Mindfulness training
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness training through yoga, 1 hour a week for 8 weeks, plus 10 minutes of daily homework
Study: 18652112
Drug: Rehabilitation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation treatment only
Study: 12870876
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL Oil of Wintergreen
Study: 12870876
Drug: 6.7 g
Normalized name: ALCOHOL 16.7 g in 30 mL TOPICAL SPRAY [HS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.7 g of Ben Gay 15%
Study: 12870876
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of Ben Gay 15%
Study: 12870876
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of Ben Gay 15% cream held in the buccal cavity for 1 minute and then expectorated
Study: 10554538
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite i.v. 1 mg bolus/2 x 1 mg infusion 1 day before ERCP
Study: 10554538
Drug: Metronidazole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 0.5 g/ofloxacin 0.2 g before and 6 hours after ERCP
Study: 8919724
Drug: Tetracycline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (500 mg orally every 6 hours for 3 days)
Study: 8919724
Drug: Co-trimoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole orally every 12 hours for 3 days)
Study: 16146617
Drug: Doxycycline hyclate
Normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline hyclate 20 mg bid
Study: 16146617
Drug: Doxycycline hyclate
Normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline hyclate 100 mg daily for eight weeks
Study: 11006368
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no growth hormone treatment)
Study: 1360714
Drug: Sulfasalicylic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalicylic drugs (SSD)
Study: 1360714
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs (NSAID)
Study: 3901360
Drug: 5 grams
Normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 grams of cefamandole in four doses over a period of 18 hours
Study: 27518403
Drug: IFN-α2b spray
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-α2b spray
Study: 10096928
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg/d for 3 days, then 500 mg/wk for 3 months)
Study: 1867419
Drug: Oral atropine
Normalized name: atropine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atropine (0.02 mg/kg)
Study: 1867419
Drug: Oral glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glycopyrrolate (0.05 mg/kg)
Study: 6617931
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of L-carnitine
Study: 28604135
Drug: SOY+RT (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOY+RT (25 g of soy protein with resistance training)
Study: 28604135
Drug: PL+RT (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PL+RT (25 g of maltodextrin placebo with resistance training)
Study: 27090817
Drug: Casein glycomacropeptide
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein glycomacropeptide (CGMP) 30 g daily
Study: 27090817
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (4800 mg oral mesalamine daily)
Study: 22792813
Drug: Transfer factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer factor oral liquid, 10 mL, 2 times daily orally, for 2 months
Study: 12957267
Drug: Vascular brachytherapy
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular brachytherapy (VBT) with a (90)Sr/(90)Y source, prescribed dose at 2 mm from the centerline of the source axis was 18.4 Gy or 23 Gy
Study: 11106135
Drug: Sertraline-Continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline-Continuation
Study: 6329547
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg enalapril twice daily (n = 18)
Study: 31272495
Drug: Oral HIVST
Normalized name: Ala-Hist IR Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIVST with biannual clinic visits plus oral HIVSTs
Study: 31252222
Drug: Biperiden (M1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden (M1 receptor antagonist, 4 mg)
Study: 28552878
Drug: LD+MCT (L-leucine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD+MCT (L-leucine 1.2 g, cholecalciferol 20 μg, 6 g of MCT)
Study: 28552878
Drug: LD+LCT (L-leucine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD+LCT (L-leucine 1.2 g, cholecalciferol 20 μg, 6 g of long-chain triglycerides)
Study: 24330691
Drug: Sildenafil (phosphodiesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (phosphodiesterase 5 inhibitor) administered daily for a short term (duration not specified)
Study: 21554816
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g α-cyclodextrin
Study: 12626865
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine analgesia
Study: 8396099
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg/day, single dose for three days)
Study: 8396099
Drug: Co-amoxiclav (tid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (tid for ten days, dosage according to manufacturer's instructions)
Study: 3002707
Drug: Omeprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (60 mg daily for 7 days)
Study: 26948252
Drug: Intravenous frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous frusemide and enteral indapamide (Group F + I)
Study: 26948252
Drug: Intravenous frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous frusemide (Group F)
Study: 24499394
Drug: Cognitive-behavioural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural group therapy (CBT)